AD Pipeline Watch: Preclinical Data Supports Role for SQ ‘1104
Subcutaneous (SQ) administration of ‘1104 performed comparably to intravenous (IV) administration in allergen-driven models of atopic dermatitis (AD), according to new preclinical data. Revolo’s ‘1104 is a first-in-class peptide that is involved in restoring immune homeostasis, impacting both the regulatory and effector arms of the immune system, effectively reducing key markers of skin inflammation and […]